Timothy Schmidt, MD @TMSchmidtMD

Assistant Professor @UWCarbone. Proud @WinshipAtEmory, @uiccom, @slusom, @XavierU alum. Clinical investigator focusing on myeloma and plasma cell disorders. Madison, WI Joined July 2018

Tweets

507
Followers

957
Following

752
Likes

2K

Muzaffar Qazilbash @Transplant_Doc

2 months ago

Real-world data provide a CARbon copy for ide-cel #mmsm #bmtsm @TMSchmidtMD @BloodPortfolio ashpublications.org/blood/article/…

0 2 13 687 1

Timothy Schmidt, MD @TMSchmidtMD

2 months ago

It was a pleasure to review the @CIBMTR analysis of ide-cel for @BloodPortfolio and for the invitation to write a commentary. Great data generated by @SurbhiSidanaMD et al confirming the safety and efficacy of ide-cel for myeloma in a real world setting. authors.elsevier.com/a/1lPab1UYwr0b7

0 4 13 899 1

Timothy Schmidt, MD @TMSchmidtMD

3 months ago

Cartitude-1 LTFU data is very exciting. Unprecedented results! But I think we need to be extremely cautious calling this a cure or functional cure. For me, cure in MM is when I can look a patient in their eyes and tell them they don't need to return to clinic. Not there yet.

3 3 21 1K 2

Robert Z. Orlowski @Myeloma_Doc

7 months ago

#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/39965175/. #mmsm

1 25 71 9K 12

Download Image

Ben Derman @bdermanmd

a year ago

How do you approach patients with AL amyloidosis with high plasmacytosis in the bone marrow (ex. 35%) but no other evidence of myeloma?

4 5 12 2K 3

Blood Cancer Talks @BloodCancerTalk

a year ago

Tune in to our new episode on quadruplets in newly diagnosed transplant-ineligible #Myeloma with @TMSchmidtMD! 🎙️ We break down the IMROZ & BENEFIT trials and how to apply them in our current practice. 🩺🔍 share.transistor.fm/s/6e20d230 Check out this short clip!

0 6 17 5K 5

Download Video

Timothy Schmidt, MD @TMSchmidtMD

a year ago

Great discussions about updates in DLBCL, MCL, and HL by @pvenugop @crdangelo9 @prekallikrein at the WI myeloma/lymphoma summit @btfoundation #lymsm

1 2 9 649 0

Download Image

Timothy Schmidt, MD @TMSchmidtMD

a year ago

Dr. Sandra Susanibar-Adaniya from @PennMedicine reviews how to treat myeloma after progression on BCMA CAR-T therapy. @btfoundation #mmsm

0 1 4 447 0

Download Image

Timothy Schmidt, MD @TMSchmidtMD

a year ago

Semantics question - how to define CAR-T toxicity duration? For example, if someone has Gr2 CRS, gets toci/dex x1 +/- acetaminophen, fever resolves promptly after toci/dex, at what point do we say it's "resolved"? Related Q (no poll) - defining ongoing vs recurrent CRS?

2 3 7 676 0

Timothy Schmidt, MD @TMSchmidtMD

a year ago

Perhaps the best figure I've found supporting the use of Dara+Len maintenance after ASCT among those receiving DaraVRd. Even among MRD- patients, PFS looks better for DR vs R. Still not sure it's worth adding for everyone, but I'm more supportive of it. rdcu.be/dPFo2

1 7 21 4K 12

Download Image

Blood Cancer Talks @BloodCancerTalk

a year ago

Coming soon! Episode on newly diagnosed transplant-ineligible #MultipleMyeloma & in-depth analysis of 𝐈𝐌𝐑𝐎𝐙 and 𝐈𝐅𝐌-𝟐𝟎𝟐𝟎/𝐁𝐄𝐍𝐄𝐅𝐈𝐓 trials with @TMSchmidtMD! #EHA24 #ASCO24 #mmsm

0 4 10 2K 4

Download Image

Timothy Schmidt, MD @TMSchmidtMD

a year ago

Does any data exist about the impact of venetoclax on autologous stem cell mobilization? Maybe somewhere in the lymphoma literature? #mmsm #bmtsm

5 3 7 3K 3

Timothy Schmidt, MD @TMSchmidtMD

a year ago

Congrats to @bdermanmd et al on this important study of extended DaraKRd for patients with newly-diagnosed myeloma. Please read my commentary (with table of outcomes from all known CD38/KRd trials), available here: rdcu.be/dJTR0 @BloodCancerJnl #mmsm #mmMRD

Ben Derman @bdermanmd

a year ago

2 19 45 10K 18

1 4 10 2K 6

Download Image

Timothy Schmidt, MD @TMSchmidtMD

a year ago

I'm a little awestruck at the sight of my fellowship research project hitting the 100 citation mark! What an amazing and timely project that was designed for me by @JKaufmanMD, Larry Boise, and @WinshipAtEmory myeloma group. Couldn't have done it without such great mentors!

1 4 35 2K 2

Download Image

Timothy Schmidt, MD @TMSchmidtMD

a year ago

I love this figure from a recent review of high risk MM by Matthew Rees and @myelomaMD in @AjHematology. Risk is a spectrum that involves so much more than cytogenetics and ISS stage! #mmsm onlinelibrary.wiley.com/doi/full/10.10…

1 16 39 4K 15

Download Image

Timothy Schmidt, MD @TMSchmidtMD

a year ago

When #myeloma patients have access to CAR-T, OS may not be improved by giving it earlier. However, line 5 is too late. For pts diagnosed late 2010s and after, triple-class refractoriness is often seen after 2L. 4.4mo med PFS for control arm in KarMMa-3 is sobering. #mmsm